Contraindicated in:
- Hypersensitivity;
- Active, untreated infection.
Use Cautiously in:
- History of tuberculosis (TB) (possibility of reactivation);
- Cirrhosis (for Crohn disease only);
- OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk;
- Lactation: Safety not established in breastfeeding;
- Pedi: Safety and effectiveness not established in children.
Exercise Extreme Caution in:
Plaque Psoriasis and Psoriatic Arthritis
- SC (Adults ): 150 mg initially and 4 wk later, then 150 mg every 12 wk.
Crohn Disease
- IV (Adults ): Induction: 600 mg initially and then at Wk 4 and Wk 8. At Wk 12, begin maintenance therapy (SUBQ) (see below).
- SC (Adults ): Maintenance: 180 mg or 360 mg at Wk 12, and then every 8 wk.
Ulcerative Colitis
- IV (Adults ): Induction: 1200 mg initially and then at Wk 4 and Wk 8. At Wk 12, begin maintenance therapy (SUBQ) (see below).
- SC (Adults ): Maintenance: 180 mg or 360 mg at Wk 12, and then every 8 wk.
Therapeutic Classification: antipsoriatics
Pharmacologic Classification: interleukin antagonists, monoclonal antibodies
Absorption: 89% absorbed following SUBQ administration. IV administration results in complete bioavailability.
Distribution: Well distributed to tissues.
Metabolism/Excretion: Broken down by catabolic processes into peptides and amino acids.
Half-Life: Plaque psoriasis: 28 days; Crohn disease: 21 days.